Metabolism - Clinical and Experimental
Volume 52, Issue 12 , Pages 1579-1585 , December 2003

Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects

  • Juris J Meier

      Affiliations

    • Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
    • Corresponding Author InformationAddress reprint requests to Dr med Juris J. Meier, Medizinische Klinik I, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, Gudrunstraße 56, 44791 Bochum, Germany
    • ,
  • Michael A Nauck

      Affiliations

    • Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany
    • ,
  • Nina Siepmann

      Affiliations

    • Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
    • ,
  • Michael Greulich

      Affiliations

    • Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
    • ,
  • Jens J Holst

      Affiliations

    • Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    • ,
  • Carolyn F Deacon

      Affiliations

    • Department of Medical Physiology, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
    • ,
  • Wolfgang E Schmidt

      Affiliations

    • Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
    • ,
  • Baptist Gallwitz

      Affiliations

    • Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany

Received 18 February 2003 ,Accepted 16 June 2003.

References 

  1. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75–85
  2. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev. 1992;8:149–177
  3. Jones IR, Owens DR, Moody AJ, et al.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia. 1987;30:707–712
  4. Amland PF, Jorde R, Aanderup S, et al.  Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol. 1985;20:315–320
  5. Nauck MA, Heimesaat MM, Ørskov C, et al.  Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301–307
  6. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia. 1997;40:984–986
  7. Meier JJ, Nauck MA, Schmidt WE, et al.  Gastric inhibitory polypeptide (GIP) (The neglected incretin revisited). Regul Peptides. 2002;107:1–13
  8. Meier JJ, Hücking K, Holst JJ, et al.  Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes. 2001;50:2497–2504
  9. Meier JJ, Nauck MA, Siepmann N, et al.  Insulin secretion following a bolus injection of gastric inhibitory polypeptide (GIP) in first-degree relatives of type 2 diabetic patients and healthy control subjects. Diabetes. 2002;51(suppl 2):A580; abstr
  10. Deacon CF, Nauck MA, Meier JJ, et al.  Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab. 2000;85:3575–3581
  11. Matthews DR, Hosker JP, Rudenski AS, et al.  Homeostasis model assessment (Insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man). Diabetologia. 1985;28:412–419
  12. Vilsbøll T, Krarup T, Deacon CF, et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613
  13. Vilsbøll T, Krarup T, Madsbad S, et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111–1119
  14. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas. Endocrinol. 1978;103:610–615
  15. Dupré J, Ross SA, Watson D, et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826–828
  16. Nauck MA, Bartels E, Ørskov C, et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76:912–917
  17. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44:929–945
  18. Halter JB, Graf RJ, Porte D. Potentiation of insulin secretory responses by plasma glucose levels in man (Evidence that hyperglycemia in diabetes compensates for imparied glucose potentiation). J Clin Endocrinol Metab. 1979;48:946–954
  19. Pfeifer MA, Halter JB, Graf R, et al.  Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide. Diabetes. 1980;29:335–340
  20. Ward WK, Bolgiano DC, McKnight B, et al.  Diminished B cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1984;74:1318–1328
  21. Jorde R, Burhol PG. The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes. Ital J Gastroenterol. 1987;19:76–78
  22. Kubota A, Yamada Y, Hayami T, et al.  Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects. Diabetes. 1996;45:1701–1705
  23. Amlind K, Ambye L, Urhammer SA, et al.  Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor (The impact on the pancreatic beta cell response and functional expression studies in Chinese hamster fibroblast cells). Diabetologia. 1998;41:1194–1198
  24. Lynn PC, Pamir N, Ng EH, et al.  Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011
  25. Nauck MA, Gabrys B, Holst JJ, et al.  Quantification of the incretin effect in first-degree relatives of type 2 diabetic patients compared to healthy control subjects. Diabetologia. 2001;44(suppl 1):A195; abstr

☆ Supported by Deutsche Forschungsgemeinschaft (DFG) Grants No. Na 203/6–1 and Ga 386/8–1, FoRUM Grant-No. F277/01, and the Deutsche Diabetes-Getellschaft (DDG).

PII: S0026-0495(03)00327-5

doi: 10.1016/S0026-0495(03)00327-5

Metabolism - Clinical and Experimental
Volume 52, Issue 12 , Pages 1579-1585 , December 2003

Article Tools

* Image Usage & Resolution